Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]

NCT05835466 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT05835466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05835466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Phase 2
Overall status
Recruiting
Start date
July 24, 2023
Completion date
December 1, 2028
Enrollment
10 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis (pmf), post essential thrombocythemia myelofibrosis (et-mf), post polycythemia vera related myelofibrosis (pv-mf)